Former CEO of failed van Eyk Research has been sentenced to 15 months’ imprisonment after admitting he breached his duties as director of a subsidiary to dishonestly retain control of the company.
Dead or broke, the class action lawyers who schemed to defraud investors in failed Banksia Securities should not escape a $21 million judgment for damages and costs, a court has heard.
Businesses bringing a class action over Sydney’s $3 billion light rail project are pursuing a bold new claim that the NSW government pay not only for damages related to their nuisance claims, but for the 40 percent commission the litigation’s funder wants from a post-trial judgment.
A judge has thrown out an underpayments class action against NSW not-for-profit Life Without Borders for failure to advance the case with due diligence and slapped the lead applicant with costs for his “unreasonable” acts during the course of the proceeding.
A judge overseeing two underpayment class actions against supermarket chain Romeo’s has declined to vary a settlement agreement to provide for distribution by Christmas, saying plaintiff firm Adero Law had not taken “all reasonable steps” to facilitate the payments.
The former chief executive of Commonwealth Bank has told a court internal auditors raised issues with CBA’s anti-money laundering and counter-terrorism financing compliance four years before AUSTRAC took action that saw the bank’s share price plummet.
The Commonwealth Bank of Australia and unit CommSec have reached an agreement with the Fair Work Ombudsman on liability in enforcement action alleging they knowingly underpaid almost 7,500 employees over $16.4 million.
Titan DMS, which provides software to car dealers across Australia, has expanded cross claims in a legal dispute with leading competitor Pentana Solutions, alleging the rival engaged in misuse of market power by threatening dealers who want to switch providers.
A class action against KPMG over the failure of six managed investment schemes for eucalyptus wood in Tasmania can’t add new claims against the accounting firm three months out from trial.
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant’s patents for blockbuster MS drug Gilenya.